This study presents a comprehensive approach for assessing multiple quality attributes of antibody-oligonucleotide conjugates ...
For the first quarter of 2026, the company's preliminary outlook reflects revenue of at least $240 million, and sequential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback